secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2026-07-23T10:46:37+00:00
Accession:  0001022079-26-000067
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quest Diagnostics Q2 revenue up 10.2% to $3.04B; raises FY2026 guidance
-----------------------------------------------------------------------

- Q2 revenue $3.04B (+10.2% YoY), organic growth 10.0%.
- Reported diluted EPS $2.84 (+15% YoY); adjusted diluted EPS $3.12 (+19.1% YoY).
- FY2026 revenue guidance raised to $11.95B-$12.05B; adjusted EPS guidance raised to $11.05-$11.25.
- Q2 cash from operations $597M, up 9.7% YoY.
- Advanced Diagnostics growth (Alzheimer's, cardiometabolic); NY approval for Haystack MRD test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000102207926000067/0001022079-26-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000102207926000067/dgx-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001022079-26-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer